share_log

In8bio | 10-Q: Q2 2024 Earnings Report

In8bio | 10-Q: Q2 2024 Earnings Report

In8bio | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/09 04:16

Moomoo AI 已提取核心信息

IN8bio reported a net loss of $8.6 million for Q2 2024, compared to $7.7 million in Q2 2023. Research and development expenses increased to $5.2 million from $4.1 million, primarily due to higher personnel costs and clinical trial expenses. General and administrative expenses remained relatively flat at $3.5 million.The company ended the quarter with $10.2 million in cash, which is expected to fund operations only into January 2025, raising substantial doubt about its ability to continue as a going concern. During Q2, IN8bio raised $3.5 million through its ATM program. The company is exploring additional financing options including equity/debt offerings and strategic partnerships to extend its runway.IN8bio continues to advance its clinical programs, including the Phase 2 trial of INB-400 for glioblastoma and Phase 1 trials of INB-200 and INB-100. Recent data presented at medical conferences showed promising results, with 92% of evaluable GBM patients exceeding median progression-free survival with INB-200/400 and 100% of leukemia patients achieving durable complete remission with INB-100 through one year.
IN8bio reported a net loss of $8.6 million for Q2 2024, compared to $7.7 million in Q2 2023. Research and development expenses increased to $5.2 million from $4.1 million, primarily due to higher personnel costs and clinical trial expenses. General and administrative expenses remained relatively flat at $3.5 million.The company ended the quarter with $10.2 million in cash, which is expected to fund operations only into January 2025, raising substantial doubt about its ability to continue as a going concern. During Q2, IN8bio raised $3.5 million through its ATM program. The company is exploring additional financing options including equity/debt offerings and strategic partnerships to extend its runway.IN8bio continues to advance its clinical programs, including the Phase 2 trial of INB-400 for glioblastoma and Phase 1 trials of INB-200 and INB-100. Recent data presented at medical conferences showed promising results, with 92% of evaluable GBM patients exceeding median progression-free survival with INB-200/400 and 100% of leukemia patients achieving durable complete remission with INB-100 through one year.
In8bio报告2024年第二季度净亏损860万美元，较2023年第二季度的770万美元有所增加。研发费用从410万美元增加至520万美元，主要由于人力成本和临床试验费用上升。一般和行政费用保持相对平稳，为350万美元。公司在季度末的现金余额为1020万美元，预计只能支持运营到2025年1月，这引发了对其持续经营能力的重大怀疑。在第二季度，In8bio通过其ATm计划募集了350万美元。公司正在探索包括股权/债务发行和战略合作伙伴关系在内的额外融资选项，以延长其资金链。In8bio继续推进其临床项目，包括针对胶质母细胞瘤的INb-400二期试验和INb-200及INb-100的一期试验。在最近的医学会议上，展示的数据显现出令人鼓舞的结果，92%的可评估胶质母细胞瘤患者在使用INb-200/400时超越了中位无进展生存期，100%的白血病患者在使用INb-100后获得了持续的完全缓解，持续时间超过一年。
In8bio报告2024年第二季度净亏损860万美元，较2023年第二季度的770万美元有所增加。研发费用从410万美元增加至520万美元，主要由于人力成本和临床试验费用上升。一般和行政费用保持相对平稳，为350万美元。公司在季度末的现金余额为1020万美元，预计只能支持运营到2025年1月，这引发了对其持续经营能力的重大怀疑。在第二季度，In8bio通过其ATm计划募集了350万美元。公司正在探索包括股权/债务发行和战略合作伙伴关系在内的额外融资选项，以延长其资金链。In8bio继续推进其临床项目，包括针对胶质母细胞瘤的INb-400二期试验和INb-200及INb-100的一期试验。在最近的医学会议上，展示的数据显现出令人鼓舞的结果，92%的可评估胶质母细胞瘤患者在使用INb-200/400时超越了中位无进展生存期，100%的白血病患者在使用INb-100后获得了持续的完全缓解，持续时间超过一年。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Impact BioMedical
    IBO
    -- 4.960
    Galecto
    GLTO
    -- 6.100
    Transcode Therapeutics
    RNAZ
    -- 1.120
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3600
    LakeShore Biopharma
    LSB
    -- 2.770
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点